Melbourne-based Amplia Therapeutics' (ASX:ATX) ACCENT clinical trial for AMP945 in treating pancreatic cancer has received approval for dose escalation and the recruitment of a third patient cohort.

The trial's Safety Review Committee evaluated the safety, pharmacokinetic, and pharmacodynamic data and concluded that dose escalation was warranted.

The company says the trial examines if adding its FAK inhibitor AMP945 to standard chemotherapy in first-line pancreatic cancer patients can improve outcomes.

Amplia Therapeutics' share price is up 12.5% over the year to date.